Lumos secures Micro-Pak manufacturing deal and order
Lumos Diagnostics (ASX:LDX) announced a new three-year contract manufacturing agreement for the innovative Micro-Pak Mold Analyser system.
Todas as matérias desta categoria, das mais recentes às mais antigas.
Lumos Diagnostics (ASX:LDX) announced a new three-year contract manufacturing agreement for the innovative Micro-Pak Mold Analyser system.
Radiopharm Theranostics (ASX:RAD) reached a clinical milestone following a positive recommendation from the Data Safety and Monitoring Committee.
Pro Medicus (ASX:PME) secured a five-year, $23 million contract with the University of Maryland Medical System.
Telix Pharmaceuticals (ASX:TLX) logged an 11% quarter-over-quarter increase in group revenue to US$230 million for the period ended March 31.
Medical technology firm ImpediMed (ASX:IPD) appointed Erik Anderson as Managing Director and CEO, effective April 7.
Mesoblast (ASX:MSB) announced that net sales for its flagship product, Ryoncil, reached US$30.3 million for the quarter ended March 31.
Amplia Therapeutics (ASX:ATX) announced a shift in its clinical programme, halting further recruitment for the AMPLICITY trial.
AFT Pharmaceuticals (ASX:AFP) recorded sustained double-digit sales growth across its entire global portfolio for the March quarter of 2026.
Paradigm Biopharmaceuticals (ASX:PAR) announced a strategic research collaboration with City St George's, University of London.
Vitura Health (ASX:VIT) announced the appointment of Justin James as its new CEO.
Emyria (ASX:EMD) has launched a targeted clinical workforce recruitment campaign in New South Wales.
Pathkey.AI (ASX:PKY) has executed a strategic services agreement with Imunexus Therapeutics.
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade